Cervical Cancer, Version 2.2015 Featured Updates to the NCCN Guidelines
Cervical Cancer, Version 2.2015 Featured Updates to the NCCN Guidelines
复制标题
DOI：
10.6004/jnccn.2015.0055
复制
发表时间：
2015-04-01
影响因子：
13.4
通讯作者：
Scavone, Jillian L.
中科院分区：
文献类型：
--
作者：
Koh, Wui-Jin;Greer, Benjamin E.;Scavone, Jillian L.
NCCN宫颈癌指南为治疗宫颈癌提供了跨学科的建议。这些NCCN指南见解总结了NCCN宫颈癌小组从2014年到2015年的讨论和主要指南更新。根据新的生存数据和FDA批准贝伐单抗治疗晚期宫颈癌的专家组审查，对复发性和转移性宫颈癌的推荐全身治疗方案进行了修改。本文概述了相关数据，并提供了关于各种联合方案的专家组决定的见解。此外，还增加了一个新的章节，以提供宫颈癌评估和手术分期的关键原则的额外指导。这篇文章强调了这一新领域的2个积极研究和争论领域：前哨淋巴结定位和保留生育能力的治疗方法。
The NCCN Guidelines for Cervical Cancer provide interdisciplinary recommendations for treating cervical cancer. These NCCN Guidelines Insights summarize the NCCN Cervical Cancer Panel's discussion and major guideline updates from 2014 and 2015. The recommended systemic therapy options for recurrent and metastatic cervical cancer were amended upon panel review of new survival data and the FDA's approval of bevacizumab for treating late-stage cervical cancer. This article outlines relevant data and provides insight into panel decisions regarding various combination regimens. Additionally, a new section was added to provide additional guidance on key principles of evaluation and surgical staging in cervical cancer. This article highlights 2 areas of active investigation and debate from this new section: sentinel lymph node mapping and fertility-sparing treatment approaches.